Shares of Aura Biosciences (NASDAQ:AURA) fell more than 20% during Monday’s trading session. This can be attributed to news of the company’s trial results for belzupacap sarotalocan, its eye cancer candidate.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The patients in the study saw an almost 89% tumor control rate. Indeed, the slowdown in tumor growth rate was statistically significant. Nonetheless, an unrelated adverse event caused one patient to stop the trial.
Is AURA Stock a Buy?
Turning to Wall Street, AURA stock has a Moderate Buy consensus rating based on two Buys assigned in the past three months. The average Aura stock price target of $28 implies 93.5% upside potential.
